Drug-induced subacute cutaneous lupus erythematosus resulting from ticlopidine [3]

International Journal of Dermatology

Volumn 45, Issue 9, 2006, Pages 1112-1114

  Reich, Adam ^a   Bialynicki Birula, Rafal ^a   Szepietowski, Jacek C ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINUCLEAR ANTIBODY; BISOPROLOL FUMARATE; CHLOROQUINE; CORTICOSTEROID; DIGOXIN; ENOXAPARIN; TICLOPIDINE;

ACUTE HEART FAILURE; AGED; ANAMNESIS; ANTIBODY DETECTION; CASE REPORT; DISEASE COURSE; DISEASE DURATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; LETTER; LUPUS LIKE SYNDROME; OCCLUSIVE CEREBROVASCULAR DISEASE; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; SKIN DEFECT; SKIN LUPUS ERYTHEMATOSUS;

ACUTE DISEASE; AGED; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; THROMBOSIS; TICLOPIDINE;

EID: 33748261832     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2006.02783.x     Document Type: Letter

References (11)

1. McTavish D, Faulds F, Goa KL. Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990; 40: 238-259.
2. Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus. A cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 1979; 115: 1409-1415.
3. Braun-Falco O, Plewig G, Wolff HH, et al. Dermatology. Berlin Heidelberg, New York: Springer Verlag, 2000: 751-832.
4. Spiera RF, Berman RS, Werner J, et al. Ticlopidine-induced lupus. A report of 4 cases. Arch Intern Med 2002; 162: 2240-2243.
5. Tsai HM, Rice L, Sarode R, et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000; 132: 794-799.
6. Steinhubl SR, Tan WA, Foody JM, et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. JAMA 1999; 281: 806-810.
7. Page Y, Tardy B, Zeni F, et al. Thrombotic throbocytopenic purpura related to ticlopidine. Lancet 1991; 337: 774-776.
8. Yosipovitch G, Rechavia E, Feinmesser M, et al. Adverse cutaneous reactions to ticlopidine in patients with coronary stents. J Am Acad Dermatol 1999; 41: 473-476.
9. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-1220.
10. Garcia CM, Carmena R, Garcia R, et al. Fixed drug eruption from ticlopidine, with positive lesional patch test. Contact Dermatitis 2001; 44: 40-41.
11. Cannavo SP, Borgia F, Guarneri F, et al. Acute generalized exanthematous pustulosis following use of ticlopidine. Br J Dermatol 2000; 142: 577-578.